Skip to main content
AAN.com
Clinical/Scientific Notes
July 27, 2016

Acute Zika infection with concurrent onset of Guillain-Barré Syndrome

October 11, 2016 issue
87 (15) 1623-1624

Abstract

A 47-year-old Tongan male returning to New Zealand after a 2-week holiday in Tonga presented with 3 days of progressive limb weakness, numbness, unsteady gait, and dyspnea. Two days before departing Tonga (6 days before neurologic symptoms), he developed leg swelling with erythematous and pustular lesions, which were treated with flucloxacillin. He had no medical history, was not taking regular medication, and had a 20 pack-year smoking history.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 2016;387:1531–1539.
2.
Lanciotti RS, Kosoy OL, Laven JJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis 2008;14:1232–1239.
3.
Esack A, Teelucksingh S, Singh N. The Guillain-Barré syndrome following dengue fever. West Indian Med J 1999;48:36–37.
4.
Ahmed S, Libman R, Wesson K, Ahmed F, Einberg K. Guillain-Barré syndrome: an unusual presentation of West Nile virus infection. Neurology 2000;55:144–146.
5.
Revised diagnostic testing for Zika, chikungunya, and dengue viruses in US Public Health Laboratories: memorandum, Centers for Disease Control and Prevention, Division of Vector-Borne Diseases. 2016. Available at: http://www.cdc.gov/zika/pdfs/denvchikvzikv-testing-algorithm.pdf. Accessed April 16, 2016.
6.
Lim SM, Koraka P, Osterhaus AD, Martina BE, West Nile virus: immunity and pathogenesis. Viruses 2011;3:811–828.
7.
Neal JW. Flaviviruses are neurotropic, but how do they invade the CNS? J Infect 2014;69:203–215.
Letters to the Editor
31 January 2017
Is rapid onset Zika virus Guillain-Barré syndrome a direct viral effect?
Paul L. Timmings, MD, Neurologist
Siu R. Bukhari W, Todd A, Gunn W,

We thank Gerardin et al. for the comments on our Zika virus (ZIKV) clinical/scientific note [1]. Our patient was of particular interest because he suffered an illness clinically and electrophysiologically indistinguishable from Guillain-Barré syndrome (GBS) which developed within a few days of acute ZIKV infection, in the context of contemporaneous Zika vireamia. [1] Concurrently obtained CSF was negative for ZIKV. Brain and spine MRI were also normal. Importantly, there was no serologic evidence of priming by previous dengue or other flaviviruses.

These clinical data suggested a direct ZIKV neural-injury mechanism, without a requirement for priming. We postulated that although molecular mimicry between ZIKV and peripheral nerve components might be relevant to antibody-induced GBS, such a rapidly developing polyradiculoneuritis mimicking GBS might also have been mediated by a direct pathogenic ZIKV effect on peripheral nerves. [2,3] This observation and ZIKV neurotropsim may also account for delayed CNS ZIKV effects in some patients. The fact that our patient was ZIKV negative in CSF suggests efficacy of the blood-brain barrier to ZIKV at that time point and strengthens the suggestion that ZIKV CNS invasion may be via neuronal transmission rather than directly across the blood brain barrier.

1. Siu R, Bukhari W, Todd A, et al. Acute Zika infection with concurrent onset of Guillain-Barré Syndrome. Neurology 2016;87:1623-1624.

2. Neal JW. Flaviviruses are neurotropic, but how do they invade the CNS? J Infect 2014;69:203-215.

3. Velandia ML, Castellanos JE. Flavivirus Neurotropism, Neuroinvasion, Neurovirulence and Neurosusceptibility: Clues to Understanding Flavivirus- and Dengue-Induced Encephalitis. In: Garcia ML, Romanowski V, editors. Viral Genomes - Molecular Structure, Diversity, Gene Expression Mechanisms and Host-Virus Interactions. Rijeka, Croatia: InTech; 2012:219-240.

For disclosures, please contact the editorial office at [email protected].

24 January 2017
Zika virus-associated Guillain-Barré syndrome: Post-infectious or para-infectious complication?
Patrick Gerardin, Clinician Researcher
V.M Cao-Lormeau, P. Tournebize, T. Cerny

Siu et al. reported the concurrent onset of polyradiculoneuritis and acute Zika virus (ZIKV) infection, while the virus was not cleared from the serum. [1] Guillain-Barre syndrome (GBS) is usually described as a post-infectious disease during which progressive flaccid paralysis develops after a phase of latency following infection. In the most common pathogenetic framework, this free interval permits the generation of sufficient levels of antibodies that crossreact by molecular mimicry with specific components of peripheral nerves, causing myelin or axonal injury, as previously documented with ZIKV infection. [2] However, this case report suggested other mechanisms. Given ZIKV cross-reactivity with dengue virus and increasing reports of ZIKV-associated GBS in dengue seropositive patients, [1,3] a hyperacute immune response is possible. [4] Given prolonged ZIKV shedding in bodily fluids, and the overlap between GBS onset and persistent shedding in fomites, a direct viral neuropathic effect may also contribute to ZIKV-associated GBS. [4] Indeed, ZIKV is able to infect cranial neural-crest cells that stem Schwann cell formation. [5] ZIKV-associated GBS could reflect a direct viral neuropathic effect on the blood-nerve barrier, allowing cross-reactive antibodies formed during previous infections to have a deleterious effect on nerve function.

1. Siu R, Bukhari W, Todd A, et al. Acute Zika infection with concurrent onset of Guillain-Barre Syndrome. Neurology 2016;87:1623-1624.

2. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 2016;387:1531-1539.

3. Parra B, Lizarazo J, Jimenez-Arango JA, et al. Guillain-Barre syndrome associated with Zika virus in Colombia. N Engl J Med 2016;375:1513-1523.

4. Dejnirattisai W, Supasa P, Wongwiwat W, et al. Dengue virus sero-cross-reactivity drives antibody dependent enhancement of infection with Zika virus. Nat Immunol 2016;17:1102-1108.

5. Bayless NL, Greenberg RS, Swigut T, Wysocka J, Blish CA. Zika Virus Infection Induces Cranial Neural Crest Cells to Produce Cytokines at Levels Detrimental for Neurogenesis. Cell Host Microbe 2016;20:423-428.

For disclosures, please contact the editorial office at [email protected].

Information & Authors

Information

Published In

Neurology®
Volume 87Number 15October 11, 2016
Pages: 1623-1624

Publication History

Received: February 25, 2016
Accepted: June 28, 2016
Published online: July 27, 2016
Published in print: October 11, 2016

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

Ronald Siu, MPH
From the Department of Neurology (R.S., W.B., P.T.), Waikato Hospital, Hamilton; and Arbovirus Reference Laboratory (A.T., W.G., Q.S.H.), Institute of Environmental Science and Research, Wellington, New Zealand.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Wajih Bukhari, MBBS
From the Department of Neurology (R.S., W.B., P.T.), Waikato Hospital, Hamilton; and Arbovirus Reference Laboratory (A.T., W.G., Q.S.H.), Institute of Environmental Science and Research, Wellington, New Zealand.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Angela Todd, MSc
From the Department of Neurology (R.S., W.B., P.T.), Waikato Hospital, Hamilton; and Arbovirus Reference Laboratory (A.T., W.G., Q.S.H.), Institute of Environmental Science and Research, Wellington, New Zealand.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Wendy Gunn, BSc
From the Department of Neurology (R.S., W.B., P.T.), Waikato Hospital, Hamilton; and Arbovirus Reference Laboratory (A.T., W.G., Q.S.H.), Institute of Environmental Science and Research, Wellington, New Zealand.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Qiu Sue Huang, PhD
From the Department of Neurology (R.S., W.B., P.T.), Waikato Hospital, Hamilton; and Arbovirus Reference Laboratory (A.T., W.G., Q.S.H.), Institute of Environmental Science and Research, Wellington, New Zealand.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Paul Timmings, MD
From the Department of Neurology (R.S., W.B., P.T.), Waikato Hospital, Hamilton; and Arbovirus Reference Laboratory (A.T., W.G., Q.S.H.), Institute of Environmental Science and Research, Wellington, New Zealand.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence to Dr. Siu: [email protected] or Dr. Timmings: [email protected]

Funding Information

Study funding: No targeted funding reported.

Funding Information

Disclosure: The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Zika Virus Infection and Development of Drug Therapeutics, Applied Microbiology, 2, 4, (782-799), (2022).https://doi.org/10.3390/applmicrobiol2040059
    Crossref
  2. Clinical Neurophysiology of Zika Virus–Related Disorders of the Peripheral Nervous System in Adults, Journal of Clinical Neurophysiology, 39, 4, (253-258), (2022).https://doi.org/10.1097/WNP.0000000000000862
    Crossref
  3. TSPO expression in a Zika virus murine infection model as an imaging target for acute infection-induced neuroinflammation, European Journal of Nuclear Medicine and Molecular Imaging, 50, 3, (742-755), (2022).https://doi.org/10.1007/s00259-022-06019-w
    Crossref
  4. Encephalitic Arboviruses of Africa: Emergence, Clinical Presentation and Neuropathogenesis, Frontiers in Immunology, 12, (2021).https://doi.org/10.3389/fimmu.2021.769942
    Crossref
  5. SARS-CoV-2 Infection and Guillain-Barré Syndrome: A Review on Potential Pathogenic Mechanisms, Frontiers in Immunology, 12, (2021).https://doi.org/10.3389/fimmu.2021.674922
    Crossref
  6. The adult brain and neurologic manifestations of the Zika virus, Zika Virus Biology, Transmission, and Pathology, (143-153), (2021).https://doi.org/10.1016/B978-0-12-820268-5.00013-4
    Crossref
  7. Emerging Infection, Vaccination, and Guillain–Barré Syndrome: A Review, Neurology and Therapy, 10, 2, (523-537), (2021).https://doi.org/10.1007/s40120-021-00261-4
    Crossref
  8. Neurological Complications of the COVID-19 Pandemic: What Have We Got So Far?, Clinical, Biological and Molecular Aspects of COVID-19, (21-31), (2021).https://doi.org/10.1007/978-3-030-59261-5_2
    Crossref
  9. Guillain-Barré syndrome related to Zika virus infection: A systematic review and meta-analysis of the clinical and electrophysiological phenotype, PLOS Neglected Tropical Diseases, 14, 4, (e0008264), (2020).https://doi.org/10.1371/journal.pntd.0008264
    Crossref
  10. Novel Coronavirus (COVID-19)-Associated Guillain–Barré Syndrome: Case Report, Journal of Clinical Neuromuscular Disease, 21, 4, (240-242), (2020).https://doi.org/10.1097/CND.0000000000000309
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share